RxDoctor Payments Data

Savannah Rachel, APRN

Family · Slidell, LANPI 1396421871

Payments from drug & device makers

$2,456in general payments, 2019–2025

Across 129 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$445
  • Novo Nordisk$260
  • Bayer$243
  • Exact Sciences$216
  • Otsuka America Pharmaceutical, Inc.$186
  • Ironwood Pharmaceuticals, Inc$166
  • plus $940 from 19 others

What the payments were for

  • Food & beverage$2,456100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,456 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$14,714
Medicare patients
104
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$38,705
MounjaroTirzepatide14$14,488
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,611
BelsomraSuvorexant13$5,613
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,125
Atorvastatin Calcium81$681
Trazodone Hcl14$589
Albuterol Sulfate HfaAlbuterol Sulfate19$532
Levothyroxine Sodium58$489
Fluticasone Propionate34$294
Paroxetine Hcl17$282
Hydrochlorothiazide62$281
Omeprazole21$269
Olmesartan Medoxomil18$232
Pantoprazole Sodium31$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$260$38,70534 claims
Lilly USA, LLCMounjaro$445$14,48814 claims
GSKTrelegy Ellipta$39$12,61118 claims
MerckBelsomra$57$5,61313 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$48958 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.

Other family in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →